Parkway Life REIT Dividend 2026: 18 Consecutive Years of DPU Growth & Healthcare Deep-Dive

Parkway Life REIT (SGX: C2PU) has achieved something no other S-REIT can match — 18 consecutive years of growing DPU since its 2007 IPO. With FY2025 DPU reaching a record 15.29 cents and a gearing ratio of just 33.4%, PLife REIT remains Singapore’s premier defensive income play. Here’s everything you need to know. This article is for informational purposes only and does not constitute financial advice.

Parkway Life REIT is Singapore’s only pure-play healthcare REIT listed on the SGX, owning 74 properties across Singapore, Japan, and France valued at approximately S$2.46 billion (as at 31 December 2025). Its Singapore portfolio — three flagship private hospitals operated by IHH Healthcare — generates over 65% of gross revenue under long-term leases with built-in CPI escalations. The Japan and France nursing home portfolios add geographic diversification with near-100% occupancy rates.

For dividend investors and CPF-OA investors seeking defensive exposure to Singapore’s ageing population theme, the Parkway Life REIT dividend history is compelling. This deep-dive covers the full DPU track record, financial health metrics, portfolio breakdown, peer comparison, and our verdict on whether PLife REIT belongs in a 2026 income portfolio.

Table of Contents

Fast Facts: Parkway Life REIT At a Glance

Here are the key metrics for Parkway Life REIT as at April 2026, sourced from the REIT’s FY2025 full-year results announcement (SGX filing, February 2026).

Data as at 31 December 2025 or April 2026 where noted. Source: Parkway Life REIT FY2025 Results Announcement (SGX, February 2026).

DPU History: 18 Years of Uninterrupted Growth

The Parkway Life REIT dividend track record is one of the most impressive in the S-REIT universe. Since its IPO in August 2007, PLife REIT has delivered uninterrupted DPU growth every single year — a record that survived the Global Financial Crisis, COVID-19 lockdowns, and the 2024 Japanese Yen depreciation headwinds. The table below shows the full-year DPU for FY2019 to FY2025 (semi-annual breakdown where available).

Source: Parkway Life REIT financial ratios page (plifereit.listedcompany.com) and SGX quarterly results announcements. Semi-annual figures are approximate where full breakdowns were not published. All data as at February 2026.

What makes this DPU record remarkable is the resilience demonstrated during periods of external stress. During COVID-19 (FY2020), PLife REIT still grew DPU by 2.2% — the Singapore hospital master leases provided near-perfect income protection. In FY2024, the introduction of a larger unit base following an equity fundraising for French nursing home acquisitions meant that on an enlarged base, DPU growth was modest at 1.1% — but management highlighted that on a like-for-like basis (excluding dilution), DPU would have grown at ~2.3%, consistent with its historical trend.

For context on broader S-REIT income plays, see our Best S-REITs Singapore 2026 guide and our Singapore REIT ETF guide for passive exposure options.

Peer Comparison: PLife REIT vs Other S-REITs

How does Parkway Life REIT stack up against other quality S-REITs? The table below compares PLife REIT against five defensive S-REITs by yield, gearing, P/NAV, and market capitalisation. Note that PLife trades at a significant premium to NAV — typical for a high-quality, low-risk REIT with an unbroken DPU growth track record. Data as at April 2026 (indicative).

Indicative data as at April 2026. Yield based on trailing 12-month DPU. All figures are approximate and for reference only — not financial advice. Sources: SGX filings, company IR pages.

The comparison reveals PLife REIT’s defining trade-off: it offers the sector’s lowest yield (3.8%) in exchange for the highest quality characteristics — lowest gearing (33.4%), strongest ICR (8.6x), longest WALE (14.49 years), and the only 18-year unbroken DPU growth streak on the SGX. Investors pay a premium (1.58x P/NAV) for this predictability. First REIT offers a much higher yield (~7.8%) but carries execution and concentration risk from its Indonesia hospital-focused portfolio.

If you’re interested in passive exposure to multiple S-REITs, our Singapore REIT ETF guide covers Lion-Phillip S-REIT ETF, NikkoAM-Straits Trading Asia Ex-Japan REIT ETF, and other options for diversified REIT exposure.

Financial Health: Gearing, ICR & Debt Profile

Parkway Life REIT’s balance sheet is among the strongest in the S-REIT sector. As at 31 December 2025:

• Gearing ratio: 33.4% — well below MAS’s 50% hard limit, giving PLife S$557.6 million of headroom before hitting 45% and S$878.5 million before 50%. This ample headroom supports future acquisitions without equity fundraising pressure.
• Interest Coverage Ratio: 8.6x — one of the highest ICRs among all SGX-listed REITs. The MAS minimum is 1.5x; PLife’s 8.6x signals near-zero refinancing risk.
• Total debt: S$886.2 million — predominantly Japanese Yen-denominated (natural hedge against Japan nursing home revenue), with a blended cost of just 1.59% p.a. This ultra-low cost of debt reflects PLife’s Japanese Yen borrowings at near-zero JPY rates.
• Weighted average debt maturity: 3.0 years — approximately 36% of debt matures by end FY2027. Management has historically been proactive in early refinancing, mitigating near-term roll-over risk.
• Interest rate hedging: 93% of interest rate exposure is hedged, providing strong visibility on financing costs through FY2027.

The main financial risk flag is the debt maturity schedule — with 36% due by end 2027, refinancing in a potentially higher-rate environment (if SORA reverses from current lows) is a watch item. However, PLife’s exceptional ICR and sponsor backing from IHH Healthcare significantly reduce this risk. For context on current interest rate dynamics affecting S-REITs, see our SORA Rate and S-REIT DPU Recovery guide.

Gearing trend over 5 years (from financial ratios page):

• FY2021: 35.4% → FY2022: 36.4% → FY2023: 35.6% → FY2024: 34.8% → FY2025: 33.4%

The consistent downward gearing trend since FY2022 reflects disciplined capital management and organic asset revaluation gains from Singapore’s private hospital portfolio.

Portfolio Analysis: Singapore, Japan & France

PLife REIT’s 74-property portfolio (S$2.46 billion AUM as at 31 December 2025) is diversified across three geographies, each with distinct characteristics.

Singapore (65% of Gross Revenue)

Three flagship hospitals operated by Parkway Hospitals Singapore Pte. Ltd. (a wholly-owned subsidiary of IHH Healthcare Berhad):

• Mount Elizabeth Hospital — 345-bed tertiary hospital in Orchard Road
• Gleneagles Hospital — 272-bed tertiary hospital in Napier Road
• Parkway East Hospital — 102-bed community hospital in Marine Parade

All three Singapore properties maintain 100% occupancy under a 20-year master lease with IHH Healthcare (renewable with CPI adjustments), providing rock-solid income visibility. IHH Healthcare (Bursa/SGX-listed, majority-owned by Khazanah Nasional and Mitsui) is one of Asia’s largest private hospital operators with a credit rating of investment grade. The Singapore master lease generates ~60.8% of total REIT gross revenue alone.

Japan (27% of Gross Revenue)

60 nursing homes and healthcare facilities across Japan, occupying 247,246 sq metres. Overall Japan portfolio occupancy is 97.7%. The Japan properties benefit from Japan’s rapidly ageing demographics — with one of the world’s highest eldery-population ratios, demand for licensed nursing facilities is structurally supported. Leases are denominated in Japanese Yen, creating foreign exchange risk (the JPY has weakened significantly vs SGD in recent years — a headwind to DPU in SGD terms).

France (8% of Gross Revenue)

11 nursing homes in France (acquired in 2023-2024), 42,631 sq metres, 100% occupancy. The French acquisition was funded by an equity raise that diluted existing unitholders in FY2024, weighing on per-unit DPU growth. However, France provides a third source of diversification in Euros, reducing concentration risk in the portfolio.

Portfolio metrics summary (as at 31 December 2025):

Source: Parkway Life REIT FY2025 Full Year Results Announcement (SGX, February 2026); plifereit.listedcompany.com. Data as at 31 December 2025.

WALE of 14.49 years (by gross revenue) is one of the longest in the entire S-REIT sector, and 90% of revenue is covered by downside-protected lease clauses. This makes PLife REIT’s income stream among the most predictable available to Singapore investors — comparable in stability to Singapore Savings Bonds but with superior long-run DPU growth. Compare that to our Singapore Savings Bonds 2026 Guide for context on the risk-return trade-off.

Key Risks for 2026

No investment is without risk. For Parkway Life REIT, these are the four most important risks to monitor in 2026:

1. Japanese Yen Currency Risk

Japan contributes 27% of gross revenue but the JPY has weakened materially against the SGD in recent years (from ~S$0.013/JPY to ~S$0.010/JPY at peak weakness in 2024). While PLife partially hedges FX exposure, sustained JPY weakness directly erodes SGD DPU from Japan properties. If Bank of Japan rate normalisation proceeds in 2026, a JPY recovery could be a positive catalyst.

2. Single-Tenant Concentration (Singapore)

IHH Healthcare / Parkway Hospitals Singapore generates ~60.8% of total gross revenue under a single master lease. While IHH is investment-grade and financially robust, tenant concentration remains a structural risk. Any material deterioration in IHH’s creditworthiness or a lease renegotiation dispute could materially affect DPU.

3. Debt Maturity Wall (FY2027)

Approximately 36% of PLife’s S$886 million debt matures by end FY2027. Refinancing in a potentially higher SORA or JPY rate environment remains a watch item, though the REIT’s 8.6x ICR and 33.4% gearing provide substantial headroom to absorb higher borrowing costs. Our SORA and S-REIT guide covers the current rate outlook in detail.

4. Premium Valuation Risk

At 1.58x P/NAV, PLife REIT is priced for near-perfection. A market de-rating — whether from rising interest rates, a broader S-REIT sector correction, or DPU growth stalling — could see the unit price re-rate lower even if fundamentals remain intact. Investors should size positions accordingly and not over-concentrate in a single defensive REIT.

Verdict: Buy, Hold or Watch?

Our view: HOLD / ACCUMULATE ON WEAKNESS

Parkway Life REIT is Singapore’s highest-quality healthcare REIT and one of the most defensive income assets on the SGX. The 18-year unbroken DPU growth track record is unique, and the combination of Singapore’s best private hospitals, 14.49-year WALE, 33.4% gearing, and 8.6x ICR makes PLife the closest thing to a “sleep well at night” REIT available to retail investors.

However, quality comes at a price. At S$4.05–S$4.10 (April 2026), PLife trades at ~1.58x NAV and yields only 3.7–3.8% on a trailing basis — a meaningful premium to the broader S-REIT sector average yield of ~5–6%. For investors seeking income maximisation, there are higher-yielding options in the S-REIT universe.

Our verdict framework:

• Buy on weakness (under S$3.60–S$3.80): At those levels, trailing yield approaches 4.2–4.5%, making the premium to NAV more palatable. The SORA environment and any JPY recovery could create re-entry opportunities.
• Hold current positions: If you already own PLife at a lower cost basis, the 18-year DPU growth streak justifies holding. Dividend reinvestment compounds well over long periods.
• Watch at current prices (S$4.05+): New investors entering at 1.58x NAV and 3.77% yield should be aware of limited margin of safety. The risk/reward is less compelling than at S$3.70 entry points seen in mid-2025.

Target yield range for accumulation: 4.0–4.5% (implying S$3.40–S$3.82 based on FY2025 DPU of 15.29¢). Not financial advice — do your own research.

For building a diversified Singapore income portfolio, consider pairing PLife REIT with higher-yielding industrial and commercial REITs. Platforms like Endowus and Syfe offer REIT-focused managed portfolios for investors who prefer passive diversification. Alternatively, explore our CPF investment strategy guide if you’re considering using CPF OA to invest in S-REITs via CPFIS.

Frequently Asked Questions

References

• Parkway Life REIT — Yearly Financial Highlights (plifereit.listedcompany.com)
• Parkway Life REIT — Financial Ratios: Gearing, NAV, DPU (plifereit.listedcompany.com)
• SGX — Parkway Life REIT (C2PU) Stock Information
• Growbeansprout — Parkway Life REIT 1H25 Dividends Analysis
• TheFinance.sg — PLife REIT FY2025 Full Year Result
• Monetary Authority of Singapore (MAS) — REIT Regulatory Framework

Disclaimer: This article is for informational and educational purposes only. It does not constitute financial advice or a recommendation to buy or sell any securities. All investment decisions involve risk. The value of units and distributions may rise or fall. Past DPU performance is not indicative of future distributions. Always conduct your own due diligence or consult a licensed financial adviser before investing.